Regulatory networks of post-translational modifications in diabetic kidney disease: from pathogenic mechanisms to therapeutic frontiers - Scorecard - MDSpire

Regulatory networks of post-translational modifications in diabetic kidney disease: from pathogenic mechanisms to therapeutic frontiers

  • By

  • Qing Jiang

  • Deqi Meng

  • Shenglong Zhu

  • Wei Tang

  • Siyuan Cui

  • June 23, 2026

  • 0 min

Share

Clinical Scorecard: Regulatory Pathways of Post-Translational Modifications in Diabetic Kidney Disease: Exploring Pathogenic Mechanisms and Therapeutic Opportunities

At a Glance

CategoryDetail
ConditionDiabetic Kidney Disease (DKD)
Key MechanismsPost-translational modifications (PTMs) such as phosphorylation, acetylation, ubiquitination, glycosylation, methylation, and SUMOylation regulate protein function and stability under diabetic stress.
Target PopulationPatients with diabetes mellitus (DM) experiencing microvascular complications.
Care SettingClinical research and therapeutic development.

Key Highlights

  • 30-40% of diabetic patients globally are affected by DKD.
  • Dysregulation of PTM networks links metabolic disturbances to renal injury.
  • Targeting PTMs may shift DKD therapy from symptomatic management to precise molecular intervention.

Guideline-Based Recommendations

Diagnosis

  • Monitor for microalbuminuria as an early indicator of DKD.

Management

  • Investigate therapeutic strategies targeting PTM-modifying enzymes.

Monitoring & Follow-up

  • Regular assessment of renal function and proteinuria in diabetic patients.

Risks

  • Progression to end-stage renal disease (ESRD) without intervention.

Patient & Prescribing Data

Diabetic patients at risk of or diagnosed with DKD.

Emerging therapies focus on modulating PTMs to prevent DKD progression.

Clinical Best Practices

  • Implement early screening for DKD in diabetic patients.
  • Consider the role of PTMs in the pathogenesis of DKD when developing treatment plans.

Related Resources & Content

Original Source(s)

Regulatory networks of post-translational modifications in diabetic kidney disease: from pathogenic mechanisms to therapeutic frontiers

  • by Qing Jiang, Deqi Meng, Shenglong Zhu, Wei Tang, Siyuan Cui

  • June 23, 2026

Related Content

Long-Term Resistance Training and Risk of Type 2 Diabetes

GLP-1 receptor agonists in neurological diseases: mechanisms and therapeutic prospects from metabolism to neuroprotection

Trajectory models of serum creatinine and 28-day mortality in critically ill patients with sepsis complicated by type 2 diabetes mellitus: a cohort study